IFN-γ-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, α-galactosylceramide

Blood

Volumn 100, Issue 5, 2002, Pages 1728-1733

  Hayakawa, Yoshihiro ^a,b,c,d   Takeda, Kazuyoshi ^a,b,c,d   Yagita, Hideo ^a,b,c,d   Smyth, Mark J ^a,b,c,d   Van Kaer, Luc ^a,b,c,d   Okumura, Ko ^a,b,c,d   Saiki, Ikuo ^a,b,c,d  

^a UNIVERSITY OF TOYAMA   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CERAMIDE DERIVATIVE; GAMMA INTERFERON; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; GALACTOSYLCERAMIDES; INTERFERON TYPE II; KILLER CELLS, NATURAL; LIGANDS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0036720437     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Mouse CD1-specific NK1 T cells: Development, specificity, and function
2. + cells: New clues to their origin, specificity, and function
3. Antigen-presenting function of mouse CD1: One molecule with two different kinds of antigenic ligands
4. CD1-mediated immune responses to glycolipids
5. CD1d-restricted and TCR-mediated activation of Vα 14 NKT cells by glycosylceramides
6. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα 14 NKT cells
7. + NKT lymphocytes
8. Critical contribution of IFN-γ and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of α-galactosylceramide
9. Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasis
10. Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells
11. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells
12. Angiogenesis in cancer, vascular, rheumatoid and other disease
13. Angiogenesis and tumor metastasis
14. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
15. The origin and function of tumor-associated macrophages
16. Tumor induction of VEGF promoter activity in stromal cells
17. + T cells requires tumor responsiveness to IFN-γ
18. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN-γ receptor expression by nonhematopoietic cells
19. Gene transfer of IFN-γ into established brain tumors represses growth by antiangiogenesis
20. Tumor cell responses to IFNγ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis
21. Evidence for the involvement of endothelial cell integrin αVβ3 in the disruption of the tumor vasculature induced by TNF and IFN-γy
22. Suppression of concanavalin A-induced hepatitis in IFNγ(-/-) mice, but not in TNF-α(-/-) mice: Role for IFN-γ in activating apoptosis of hepatocytes
23. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4
24. + T cells and their IFN-γ production in the generalized Shwartzman reaction
25. Inhibition of tumor angiogenesis by a synthetic cell-adhesive polypeptide containing the Arg-Gly-Asp (RGD) sequence of fibronectin, poly(RGD)
26. Vessel cooption, regression, and growth in tumors mediated by anglopoietins and VEGF
27. Isolation of putative progenitor endothelial cells for angiogenesis
28. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo
29. Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo
30. Fractalkine-mediated endothelial cell injury by NK cells
31. Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: Putative relation with BCL-2-mediated neovascularization
32. Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily
33. VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo
34. Inhibition of tumorinduced angiogenesis by the administration of recombinant interferon-gamma followed by a synthetic lipid-A subunit analogue (GLA-60)
35. Inhibition of angiogenesis in vivo by interleukin 12
36. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
37. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell crosstalk
38. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12
39. Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12
40. The anti-tumor activity of IL-12: Mechanisms of innate immunity that are model and dose dependent
41. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells
42. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways